STAT - Reporting from the frontiers of health and medicine

STAT - Reporting from the frontiers of health and medicine

It is also possible that the amyloid hypothesis is somewhat on the right track, but just need to target the right part of the pathway. For example no one has designed any clinical trial yet according to this article recently published in the journal Nature (a Gal3 inhibitor drug, belapectin, currently exists): Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease https://www.nature.com/articles/s41418-019-0348-z



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More